A proprietary injectable radioactive agent—99mTc apcitide—used for scintigraphic imaging of veins to identify acute venous thrombosis in the lower legs.
References in periodicals archive ?
Preparative HPLC was performed with an Acuflow Series III pump connected with an Acutect 500 UV/vis detector using an Econosil ODS column (250 x 22 mm, 10[mu]m, Alltech; detection: 278 nm; flow rate: 3.
In particular, we noted significant interest in AcuTect at the Society of Nuclear Medicine meeting in June.
The study confirmed the correlation between AcuTect and contrast venography, the internationally recognized gold standard for detecting deep vein thrombosis.
A Phase III multicenter study of AcuTect involving 243 patients, led by clinicians at Centre Hospitalier Universitaire de Montreal, found that AcuTect(TM) (Technetium Tc 99m Apcitide Injection) has high sensitivity for imaging acute venous clots in the deep veins of the legs (deep vein thrombosis).
Clinical follow-up studies of patients with negative AcuTect scans have not been performed to determine if negative image findings mean the absence of acute venous thrombosis.
After administration of AcuTect, as with the administration of other intravenous drugs, patients with a history of drug reactions, other allergies, or immune system disorders should be observed for several hours.
Revenue from AcuTect sales in the first quarter of 1999 increased 66 percent over revenue from AcuTect sales in the fourth quarter of 1998 when the product was launched.
As outlined earlier this year, we are concentrating our marketing and sales efforts on increasing awareness and acceptance of AcuTect among the specialists and referring physicians who will benefit most from this technology.
Peters, President of Nycomed Amersham Imaging, headquartered in Princeton, NJ, added, "At Nycomed, we continue to be enthusiastic about the potential of the AcuTect and NeoTect(tm) products developed by our partner, Diatide.
0 million milestone payment for Diatide's submission to the FDA of its NDA for AcuTect from Nycomed Amersham.
This increase reflects the Company's marketing and sales investments for the launch of AcuTect and increased funding of therapeutic products.
This decrease reflects higher clinical and regulatory costs in 1997 relating to AcuTect(TM) and NeoTect(TM) , offset by marketing and sales initiatives for the launch of AcuTect in 1998.